Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF-κB activity in SW620 human colon cancer cells

Lee,Won Sup; Yun,Jeong Won; Nagappan,Arulkumar; Park,Hyeon Soo; Lu,Jing Nan; Kim,Hye Jung; Chang,Seong-Hwan; Kim,Dong Chul; Lee,Jeong-Hee; Jung,Jin-Myung; Hong,Soon Chan; Ha,Woo Song; Kim,Gonsup

doi:10.3892/or.2015.3890

Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF-κB activity in SW620 human colon cancer cells

Authors:
- Won Sup Lee
- Jeong Won Yun
- Arulkumar Nagappan
- Hyeon Soo Park
- Jing Nan Lu
- Hye Jung Kim
- Seong-Hwan Chang
- Dong Chul Kim
- Jeong-Hee Lee
- Jin-Myung Jung
- Soon Chan Hong
- Woo Song Ha
- Gonsup Kim
View Affiliations

Affiliations: Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, School of Veterinary and Research Institute of Life Science, Institute of Life Science, Gyeongsang National University, Jinju 660-701, Republic of Korea, Department of Pharmacology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, Department of Surgery, Konkuk University School of Medicine, Seoul 143-701, Republic of Korea, Department of Pathology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, Department of Neurosurgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, Department of Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea
Published online on: March 31, 2015 https://doi.org/10.3892/or.2015.3890
Pages: 2940-2946

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tetraarsenic hexoxide (As4O6) has been used in Korean traditional medicine for the treatment of cancer since the late 1980's, and arsenic trioxide (As2O3) is currently used as a chemotherapeutic agent. Previous studies suggest that the As4O6-induced cell death pathway is different from that of As2O3 and its mechanism of anticancer activity remains unclear. Nuclear factor (NF)-κB is a well-known transcription factor involved in cell proliferation, invasion and metastasis. Hence, in the present study, we investigated the effects of As4O6 on NF-κB activity and NF-κB-regulated gene expression in vitro and in vivo. The cytotoxicity assay revealed that As4O6 inhibited the growth of SW620 cells in a dose-dependent manner, and the half maximal inhibitory concentration (IC50) was ~1 µM after a 48 h treatment. As4O6 suppressed NF-κB activation and suppressed inhibitory κBα (IκBα) phosphorylation stimulated by tumor necrosis factor (TNF). As4O6 also suppressed downstream NF-κB-regulated proteins involved in cancer anti-apoptosis, proliferation, invasion and metastasis. In addition, As4O6 marginally suppressed tumor growth and the anti-NF-κB activity was confirmed using an in vivo xenograft mouse model in which animals were injected with SW620 cells. The present study provides evidence that As4O6 has anticancer properties through suppression of NF-κB activity and NF-κB-mediated cellular responses.

View Figures

View References

1	El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
2	Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL). II Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
3	Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 94:3315–3324. 1999.PubMed/NCBI
4	Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E and Barlogie B: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:1835–1837. 2002. View Article : Google Scholar : PubMed/NCBI
5	Lin YC, Li DR and Lin W: Relationship between radiotherapy enhancing effect of arsenic trioxide and the proliferation and apoptosis of related protein in nasopharyngeal carcinoma patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 27:704–707. 2007.In Chinese. PubMed/NCBI
6	Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, et al: Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. Am J Hematol. 86:796–800. 2011. View Article : Google Scholar : PubMed/NCBI
7	Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D and Crawford ED: Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 106:2624–2629. 2006. View Article : Google Scholar : PubMed/NCBI
8	Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ, Bae IJ, Lee YJ, Shin JC, Kim CK and Ahn WS: Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway. Int J Oncol. 30:1129–1135. 2007.PubMed/NCBI
9	Han MH, Lee WS, Lu JN, Yun JW, Kim G, Jung JM, Kim GY, Lee SJ, Kim WJ and Choi YH: Tetraarsenic hexoxide induces Beclin-1-induced autophagic cell death as well as caspase-dependent apoptosis in u937 human leukemic cells. Evid Based Complement Alternat Med. 2012:2014142012. View Article : Google Scholar
10	Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS Jr: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 19:5785–5799. 1999.PubMed/NCBI
11	Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, Lotan R, Khuri FR and Hong WK: Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst. 96:1536–1548. 2004. View Article : Google Scholar : PubMed/NCBI
12	Jang JS, Lee WS, Lee JS, Kim HW, Ko GH and Ha WS: The expression of thymidine phosphorylase in cancer-infiltrating inflammatory cells in stomach cancer. J Korean Med Sci. 22(Suppl 22): S109–S114. 2007. View Article : Google Scholar : PubMed/NCBI
13	Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
14	Motokura T and Arnold A: PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer. 7:89–95. 1993. View Article : Google Scholar : PubMed/NCBI
15	Gilmore TD: Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kim DS, Park SS, Nam BH, Kim IH and Kim SY: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 66:10936–10943. 2006. View Article : Google Scholar : PubMed/NCBI
17	Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B and Deeg HJ: NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 106:3917–3925. 2005. View Article : Google Scholar : PubMed/NCBI
18	Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
19	Bogenrieder T and Herlyn M: Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536. 2003. View Article : Google Scholar : PubMed/NCBI
20	Vihinen P and Kähäri VM: Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
21	Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar
22	Correia M, Cravo M, Marques-Vidal P, Grimble R, Dias-Pereira A, Faias S and Nobre-Leitão C: Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. Clin Nutr. 26:728–735. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chen ZJ, Parent L and Maniatis T: Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 84:853–862. 1996. View Article : Google Scholar : PubMed/NCBI